title: Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
abstract: The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).
authors.affiliation: Department of Neurosciences, Rheumatology Division, University of Padova, Italy. chiara.briani@unipd.it
authors.forename: C
authors.initials: C
authors.lastname: Briani
authors.forename: G
authors.initials: G
authors.lastname: Zara
authors.forename: R
authors.initials: R
authors.lastname: Rondinone
authors.forename: S
authors.initials: S
authors.lastname: Della Libera
authors.forename: M
authors.initials: M
authors.lastname: Ermani
authors.forename: S
authors.initials: S
authors.lastname: Ruggero
authors.forename: A
authors.initials: A
authors.lastname: Ghirardello
authors.forename: S
authors.initials: S
authors.lastname: Zampieri
authors.forename: A
authors.initials: A
authors.lastname: Doria
mesh_terms: D000328:Adult; D004594:Electrophysiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000175:diagnosis / Q000209:etiology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis; D011446:Prospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide